Status:

COMPLETED

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Lead Sponsor:

Asahi Kasei Pharma Corporation

Conditions:

Deep Mycosis

Eligibility:

All Genders

20+ years

Phase:

PHASE3

Brief Summary

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis...

Eligibility Criteria

Inclusion

  • Main
  • Patients must have the below proven, probable or possible deep mycosis;
  • invasive aspergillosis
  • chronic pulmonary aspergillosis
  • mucormycosis
  • cryptococcosis
  • Female patients must be non-lactating and at no risk for pregnancy.
  • Main

Exclusion

  • Women who are pregnant or breastfeeding.
  • Patients with hypersensitivity to any of the components of the azole class of antifungals or the investigational product.
  • Patients at high risk for QT/QTc prolongation, or patients with risk factors for torsades de pointes, or taking concomitant medications known to prolong the QT/QTc interval.
  • Patients with a history of short QT syndrome.
  • Patients with liver dysfunction at enrollment.
  • Patients with moderate to severe kidney dysfunction at enrollment.
  • Patients who receive prohibited concomitant drugs.
  • Patients with any other fungal infection other than Aspergillus species, order Mucorales, or Cryptococcus species.
  • Patients who are not expected to survive study duration.
  • Patients with an underlying disease, complication or general condition that would complicate safety and efficacy evaluations.
  • Patients with a history of taking voriconazole for deep mycosis and showing no response to this treatment.
  • Patients taking systemic antifungals who are unable to stop taking these drugs during the study, or who are showing signs of improvement in their symptoms of deep mycosis as a result of these drugs.

Key Trial Info

Start Date :

April 16 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 21 2021

Estimated Enrollment :

103 Patients enrolled

Trial Details

Trial ID

NCT03471988

Start Date

April 16 2018

End Date

April 21 2021

Last Update

May 14 2021

Active Locations (33)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (33 locations)

1

Research site

Nagakute, Aichi-ken, Japan

2

Research site

Nagoya, Aichi-ken, Japan

3

Research site

Seto, Aichi-ken, Japan

4

Research site

Higashiku, Fukuoka, Japan